Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797453 | 0.74 | MGMT (0.35) | — | |
| Hydrochloric Acid SCHEMBL7809520 | 0.72 | MGMT (0.35) | — | |
| SCHEMBL349903 | 0.71 | CYP11B1 (0.42) | TDP1LMNASMN1; SMN2KDM4ERAB9A | |
| SCHEMBL559559 | 0.71 | TAAR1 (0.56) | ADRA1DTDP1LMNATSHRTAAR1 | |
| SCHEMBL2752018 | 0.70 | SMN1; SMN2 (0.46) | ADRA1DTDP1LMNATSHRTAAR1 | |
| SCHEMBL346321 | 0.70 | ADRA1D (0.49) | ADRA1DLMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL7797466 | 0.70 | ALDH1A1 (0.31) | SMN1; SMN2KMT2ARAB9A | |
| SCHEMBL649075 | 0.69 | ALDH1A1 (0.46) | ADRA1DTDP1LMNATSHRTAAR1 | |
| SCHEMBL8447530 | 0.69 | CYP2C9 (0.45) | ADRA1DTDP1LMNATSHRTAAR1 | |
| SCHEMBL17595404 | 0.69 | ALDH1A1 (0.43) | TDP1SMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7399868-B2 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399868-B2 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| WO-1999051593-A1 | 4-THIONAPHTHYL-1H-IMIDAZOLES WITH ALPHA-2-ADRENERGIC ACTIVITY | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0889891-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0889891-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5750720-A | ALPHA-ADRENORECEPTORS AND CENTRAL NERVOUS SYSTEMS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997035858-A1 | 4-[(THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING α2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035857-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035857-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5621113-A | ALPHA 2 ADRENOCEPTOR AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5621113-A | ALPHA 2 ADRENOCEPTOR AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5621113-A | ALPHA 2 ADRENOCEPTOR AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ADRB2, ADRA2C, ADRA2A | ADRA1D 8/4885TDP1 1165/4885LMNA 3388/4885 |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ADRA2B, ADRA1B, ADRB1 | ADRA1D 12/4885TDP1 2249/4885LMNA 2516/4885 |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | ADRA1D 140/4885TDP1 3495/4885LMNA 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.